Business Daily from THE HINDU group of publications
Tuesday, Jul 15, 2008
ePaper | Mobile/PDA Version | Audio


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Alliances & Joint Ventures
Jubilant arm in drug discovery pact with US firm

Our Bureau

New Delhi, July 14 Jubilant Biosys Ltd, a subsidiary of Jubilant Organosys Ltd, announced a drug discovery partnership with US-based biotech company Amgen Inc.

The two companies will collaborate to develop a portfolio of novel drugs in new target areas of interest across multiple therapeutic areas. Under the agreement, Jubilant will develop early pre-clinical candidates emanating from Amgen’s early discovery efforts for an initial term of three years. Amgen will have responsibility for the subsequent pre-clinical and clinical development and commercialisation.

Amgen will own the drugs developed under the collaboration with worldwide commercialisation rights. Jubilant Biosys will partner in early-preclinical development effort from its state of the art Jubilant Research Centre in Bangalore.

The financial terms include a combination of research funding and success-based milestones paid to Jubilant during pre-clinical and clinical development for multiple projects undertaken by the collaboration. Though the company did not give any details on the exact commercial terms with Amgen, it said the total financial milestone value is subject to successful development and commercialisation of the portfolio of novel drugs.

Commenting on the development, Mr Shyam S. Bhartia, Chairman and Managing Director, Jubilant Organosys, said, “We are very pleased to expand our relationship with Amgen. This collaboration leverages the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development, combining these strengths with Amgen, the world’s largest research driven Biotech company, to deliver cost-effective new products that will help patients around the world. This partnership continues to demonstrate Jubilant’s strategy to be India’s largest innovation driven integrated pharmaceutical service provider supporting the global pharmaceutical industry.”

Related Stories:
Jubilant bags $92-m worth contract research deals
Jubilant Energy finds oil & gas in Cauvery
Jubilant to grow retail presence in southern cities
Jubilant Organosys posts 40% growth in Q3 net
Jubilant arm teams up with Forest Lab

More Stories on : Alliances & Joint Ventures | Pharmaceuticals | Research & Development

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Zandu Pharma scales new peak


V Guard declares 25% dividend
Era Infra bags BHEL contract
BEML bags 2 African orders
Ranbaxy refutes allegations by US Govt
Ranbaxy: Uncertainty about USFDA investigation
HC refuses to grant interim order to Dunlop
Continental opens electronic facility in Bangalore
TVS Cherry plans to set up third facility
SRF acquiring South African belting fabrics firm
Jubilant arm in drug discovery pact with US firm
HPCL ties up with Chhattisgarh
Emaar to infuse $150 m into specific projects
Foreign firms to pick up stake in Eldeco Infra for Rs 196 cr
Panna-Mukta gas supply to normalise this week
Volkswagen to double its passenger vehicle sales


Life



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line